Molecular Testing for Thyroid Nodules: The Advance That Can Help You Avoid Unnecessary Surgery
Written by John P. Sabra, MD FACS
Updated May 2026
Educational only. This article is not medical advice. Always consult your physician about your individual situation.
Every year, thousands of patients with thyroid nodules undergo surgery that turns out to be unnecessary. The nodule is removed, the pathologist examines it, and the verdict is benign. All of it avoidable, had the right information been available beforehand.
Molecular and genetic testing exists to close that gap. It is one of the most significant advances in thyroid care of the past decade — and it is not yet available or offered at every practice. That gap in availability is something you can and should address before your biopsy is scheduled, not after you are already holding an indeterminate result.
Why Molecular Testing Exists: The Problem It Was Built to Solve
For a specific subset of nodules, standard cytology reaches a ceiling — a Bethesda III or IV result. Before molecular testing was available, the default answer was often diagnostic surgery. The fundamental problem: among all patients who receive an indeterminate result and proceed to surgery, studies consistently show that 60 to 80% of the removed nodules turn out to be benign. The surgery was unnecessary for the majority of patients who had it.
Approximately 570,000 thyroid FNA biopsies are performed in the United States each year. Roughly 15 to 25% return indeterminate results — meaning approximately 85,000 to 140,000 patients annually receive a result that cannot be resolved by cytology alone. Molecular testing has the potential to spare most of those patients from unnecessary surgery.
How Molecular Testing Works
Molecular testing analyzes the genetic material in the cells collected during your FNA biopsy — measuring which genes are being expressed, identifying specific mutations or gene fusions, or both. By comparing the genetic signature of your sample against a large reference database of known benign and malignant thyroid nodules, the platform produces a classification that goes beyond what the pathologist can see under a microscope.
The Two Major Platforms: Afirma and ThyroSeq
| Feature | Afirma GEC/GSC | ThyroSeq v3 |
|---|---|---|
| Technology | Gene expression classifier (RNA) | DNA and RNA sequencing for specific mutations and gene fusions |
| Benign result name | Genomic Benign | Negative for mutations/fusions |
| Added information | Binary benign or suspicious call | Identifies which specific mutations are present — can inform surgical planning |
| Sample requirement | Uses existing FNA material in most cases | Uses existing FNA material in most cases |
A genomic benign result does not reduce malignancy risk to zero. What it does is reduce it substantially — typically to below 5% for Bethesda III nodules and below 10 to 15% for Bethesda IV nodules. For most patients, this reduction is sufficient to support a decision to avoid surgery and proceed with surveillance instead.
Ask Before Your Biopsy, Not After
Molecular testing can only help you if the conditions for it are in place before your biopsy is performed. Not every physician who performs thyroid biopsies incorporates molecular testing into their practice. If your biopsy is done at a facility that does not offer it and your result comes back indeterminate, you may face a choice between a second biopsy or proceeding directly to surgery — an outcome avoidable with a single conversation before your biopsy is scheduled.
Questions to Ask Before You Schedule Your Biopsy
| Question | Why It Matters |
|---|---|
| Does your practice offer molecular testing for indeterminate results? | If the answer is no, understand what happens next if your result is indeterminate. Without it, surgery may become the only path to a definitive answer. |
| Which platform do you use, and is my sample preserved at the time of biopsy? | If the sample is not preserved at collection, the opportunity for testing may be lost. |
| Is pathology reviewed by a cytopathologist with thyroid experience? | A dedicated thyroid cytopathologist will produce more reliable classifications. |
| What is your institution’s indeterminate rate? | A rate of 15 to 25% is consistent with published benchmarks. |
| If my result is indeterminate, what is the next step and timeline? | Understanding the pathway in advance reduces anxiety after the fact. |
Insurance Coverage and Cost
Molecular testing list prices range from approximately $2,000 to $5,000 per test. However, most major commercial insurers and Medicare now cover Afirma and ThyroSeq for patients with indeterminate results when specific criteria are met — typically a documented Bethesda III or IV result. Both testing companies offer patient assistance programs for patients whose coverage is denied.
The Bottom Line
Molecular testing for thyroid nodules is not experimental, not obscure, and not reserved for patients at major academic centers. It is a clinically validated tool available today, covered by most major insurance plans, and capable of sparing the majority of patients with indeterminate biopsy results from unnecessary surgery. The patients who benefit are the ones who end up in a practice where it is offered.
References
- Haugen BR, et al. 2015 ATA Management Guidelines for Thyroid Nodules and DTC. Thyroid. 2016.
- American Thyroid Association — Fine-Needle Aspiration Biopsy of Thyroid Nodules.
- ATA Professional Guidelines.
This article was written by John P. Sabra, MD FACS and is intended for patient education only. It does not constitute medical advice and does not replace a consultation with your physician.
More from the Advanced Thyroid Care series
Ready to Talk to a Specialist?
A thyroid specialist can review your specific results, answer your questions, and help you understand exactly what your next steps should be. The ATLAS network connects you with experienced thyroid and parathyroid expert physicians who focus on thyroid disease.
Find a Thyroid Specialist Near You →